The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Mov Disord. 2011 Apr;26(5):801-6. doi: 10.1002/mds.23470.


Objectives: Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis.

Methods: Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.

Results: The pooling of data from well-designed observational studies documented that both pergolide (RR = 3.05 [1.71-5.44]) and cabergoline (RR = 6.38 [3.17-12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.

Conclusions: The present meta-analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Databases, Factual / statistics & numerical data
  • Dopamine Agonists / adverse effects*
  • Heart Valve Diseases / chemically induced*
  • Humans
  • Models, Statistical
  • Observation
  • Parkinson Disease / drug therapy*
  • Risk Factors


  • Dopamine Agonists